title: ÐÐ¾Ð¸ÑÐº ÑÐ¾Ð¼Ð°ÑÐ¸ÑÐµÑÐºÐ¸Ñ Ð¼ÑÑÐ°ÑÐ¸Ð¹, Ð¾ÐºÐ°Ð·ÑÐ²Ð°ÑÑÐ¸Ñ Ð²Ð»Ð¸ÑÐ½Ð¸Ðµ Ð½Ð° ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÑ Ðº ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ°Ð¼Ð¸ EGFR
title: Ð¼Ð°Ð³Ð¸ÑÑÐµÑÑÐºÐ°Ñ Ð´Ð¸ÑÑÐµÑÑÐ°ÑÐ¸Ñ
titleType: Subtitle
Creators: name: Ð¡ÑÑÐµÐ»ÐºÐ¾Ð²Ð°, Ð¢Ð°ÑÑÑÐ½Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2016
Subjects: Ð²ÑÑÐ¾ÐºÐ¾Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸ÑÐµÐ»ÑÐ½ÑÐ¹ Ð³ÐµÐ½Ð¾Ð¼Ð½ÑÐ¹ Ð°Ð½Ð°Ð»Ð¸Ð·
Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½Ð¾-Ð³ÐµÐ½ÐµÑÐ¸ÑÐµÑÐºÐ¸Ð¹ Ð°Ð½Ð°Ð»Ð¸Ð·
Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½Ð°Ñ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸Ñ
Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÑ
ÑÐ°Ðº ÑÐ¾Ð»ÑÑÐ¾Ð¹ ÐºÐ¸ÑÐºÐ¸
high-performance genomic analysis
molecular genetic analysis
molecular Oncology
inhibitors
colon cancer

description: Ð ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð¾Ð±ÑÐµÐºÑÐ¾Ð² Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ Ð±ÑÐ»Ð¸ Ð²ÑÐ±ÑÐ°Ð½Ñ Ð¾Ð±ÑÐ°Ð·ÑÑ ÐÐÐ Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸ ÑÐ¾Ð»ÑÑÐ¾Ð¹ ÐºÐ¸ÑÐºÐ¸ Ð±ÐµÐ· Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð² Ð³ÐµÐ½Ð°Ñ KRAS, NRAS, BRAF. ÐÐ»Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð±ÑÐ»Ð° Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð° ÐºÐ¾Ð»Ð»ÐµÐºÑÐ¸Ñ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² ÐÐÐ Ð±Ð¾Ð»ÑÐ½ÑÑ ÑÐ°ÐºÐ¾Ð¼ ÑÐ¾Ð»ÑÑÐ¾Ð¹ ÐºÐ¸ÑÐºÐ¸, ÑÑÐ¾ÑÐ¼Ð¸ÑÐ¾Ð²Ð°Ð½Ð½Ð°Ñ Ð² Ð»Ð°Ð±Ð¾ÑÐ°ÑÐ¾ÑÐ¸Ð¸ Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½Ð¾Ð¹ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¤ÐÐÐ£ Â«ÐÐÐ Ð¾Ð½ÐºÐ¾Ð»Ð¾Ð³Ð¸Ð¸ Ð¸Ð¼. Ð.Ð. ÐÐµÑÑÐ¾Ð²Ð°Â». ÐÐ· 120 ÑÐ»ÑÑÐ°ÐµÐ² ÐºÐ¾Ð»Ð¾ÑÐµÐºÑÐ°Ð»ÑÐ½Ð¾Ð³Ð¾ ÑÐ°ÐºÐ° Ð´Ð»Ñ ÐºÐ»Ð¸Ð½Ð¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ñ ÑÑÑÐµÐºÑÐ¸Ð²Ð½Ð¾ÑÑÐ¸ ÑÐµÑÐ°Ð¿Ð¸Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ°Ð¼Ð¸ EGFR Ð±ÑÐ»Ð¾ Ð¾ÑÐ¾Ð±ÑÐ°Ð½Ð¾ 20 Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð² Ð¾Ð¿ÑÑÐ¾Ð»ÐµÐ²Ð¾Ð¹ ÑÐºÐ°Ð½Ð¸ ÐºÐ¾ÑÐ¾ÑÑÑ Ð½Ðµ Ð±ÑÐ»Ð¾ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¾ Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð² Ð³ÐµÐ½Ð°Ñ KRAS, NRAS, BRAF. ÐÐ»Ñ Ð´Ð¾Ð¿Ð¾Ð»Ð½Ð¸ÑÐµÐ»ÑÐ½Ð¾Ð¹ ÑÐµÐ»ÐµÐºÑÐ¸Ð¸ Ð¾Ð±ÑÐ°Ð·ÑÐ¾Ð² Ð²ÑÐ¿Ð¾Ð»Ð½ÐµÐ½ Ð°Ð½Ð°Ð»Ð¸Ð· Ð¼ÑÑÐ°ÑÐ¸Ð¹ Ð² Ð³ÐµÐ½Ðµ PIK3CA. Ð¡ÑÐ°ÑÑÑ Ð³ÐµÐ½Ð° PIK3CA Ð² Ð¾Ð¿ÑÑÐ¾Ð»Ð¸ Ð¾ÑÐµÐ½Ð¸Ð²Ð°Ð»Ð¸, Ð¸ÑÐ¿Ð¾Ð»ÑÐ·ÑÑ ÐºÐ¾Ð¼Ð±Ð¸Ð½Ð°ÑÐ¸Ñ Ð¼ÐµÑÐ¾Ð´Ð¾Ð²: Ð°Ð»Ð»ÐµÐ»Ñ-ÑÐ¿ÐµÑÐ¸ÑÐ¸ÑÐµÑÐºÑÑ ÐÐ¦Ð  (ÐÐ¡-ÐÐ¦Ð ), Ð°Ð½Ð°Ð»Ð¸Ð· ÐºÐ¸Ð½ÐµÑÐ¸ÐºÐ¸ Ð¿Ð»Ð°Ð²Ð»ÐµÐ½Ð¸Ñ Ñ Ð²ÑÑÐ¾ÐºÐ¸Ð¼ ÑÐ°Ð·ÑÐµÑÐµÐ½Ð¸ÐµÐ¼ (High Resolution Melting Analysis, HRMA) Ð¸ ÑÐµÐºÐ²ÐµÐ½Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ðµ. Ð 6 ÑÐ»ÑÑÐ°ÑÑ Ð¸Ð· 20 Ð¿ÑÐ¸ Ð»ÐµÑÐµÐ½Ð¸Ð¸ Ð¸Ð½Ð³Ð¸Ð±Ð¸ÑÐ¾ÑÐ°Ð¼Ð¸ EGFR Ð½Ð°Ð±Ð»ÑÐ´Ð°Ð»Ð°ÑÑ Ð¿ÑÐ¾Ð³ÑÐµÑÑÐ¸Ñ Ð·Ð°Ð±Ð¾Ð»ÐµÐ²Ð°Ð½Ð¸Ñ. ÐÐ¿ÑÑÐ¾Ð»ÐµÐ²ÑÑ ÑÐºÐ°Ð½Ñ, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÑ Ð¾Ñ Ð´Ð°Ð½Ð½ÑÑ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð², Ð±ÑÐ»Ð¾ ÑÐµÑÐµÐ½Ð¾ Ð¿Ð¾Ð´Ð²ÐµÑÐ³Ð½ÑÑÑ Ð²ÑÑÐ¾ÐºÐ¾Ð¿ÑÐ¾Ð¸Ð·Ð²Ð¾Ð´Ð¸ÑÐµÐ»ÑÐ½Ð¾Ð¼Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¼Ñ Ð°Ð½Ð°Ð»Ð¸Ð·Ñ Ñ ÑÐµÐ»ÑÑ Ð²ÑÑÐ²Ð»ÐµÐ½Ð¸Ñ Ð¼Ð¾Ð»ÐµÐºÑÐ»ÑÑÐ½ÑÑ Ð¿ÑÐµÐ´Ð¸ÐºÑÐ¾ÑÐ¾Ð² ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ðº Ð°Ð½ÑÐ¸-EGFR ÑÐµÑÐ°Ð¿Ð¸Ð¸. Ð Ð´Ð°Ð½Ð½Ð¾Ð¹ ÑÐ°Ð±Ð¾ÑÐµ Ð¿ÑÐµÐ´Ð»Ð¾Ð¶ÐµÐ½ Ð°Ð»Ð³Ð¾ÑÐ¸ÑÐ¼ Ð±Ð¸Ð¾Ð¸Ð½ÑÐ¾ÑÐ¼Ð°ÑÐ¸ÑÐµÑÐºÐ¾Ð³Ð¾ Ð°Ð½Ð°Ð»Ð¸Ð·Ð° Ð¸ ÑÐ¸Ð»ÑÑÑÐ°ÑÐ¸Ð¸ Ð¼ÑÑÐ°ÑÐ¸Ð¹, Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÑÑÐ¸Ð¹ Ð²ÑÑÐ²Ð¸ÑÑ Ð½Ð°Ð¸Ð±Ð¾Ð»ÐµÐµ Ð²ÐµÑÐ¾ÑÑÐ½ÑÐµ Ð´ÐµÑÐµÑÐ¼Ð¸Ð½Ð°Ð½ÑÑ ÑÑÐ²ÑÑÐ²Ð¸ÑÐµÐ»ÑÐ½Ð¾ÑÑÐ¸ Ð¾Ð¿ÑÑÐ¾Ð»Ð¸ Ðº ÑÐ°ÑÐ³ÐµÑÐ½Ð¾Ð¹ ÑÐµÑÐ°Ð¿Ð¸Ð¸.
description: The study includes KRAS/NRAS/BRAF mutation-negative tumor DNA samples obtained from elderly colorectal cancer (CRC) patients. Tumor samples were selected from the laboratory DNA collection of CRC cases (n=120) treated in N.N. Petrov Institute of Oncology and undergone molecular analysis for KRAS/NRAS/BRAF. Twenty cases without mutations in KRAS, NRAS, BRAF were recruited for anti-EGFR inhibitors clinical trial. For these cases, additional molecular test for the presence of PIK3CA mutations was done. Analysis of PIK3CA alterations was performed using combination of allele-specific PCR (AS-PCR), High Resolution Melting Analysis (HRMA) and sequencing.Among 20 cases enrolled in clinical trial, 6 progressed upon treatment. For these patients, we performed next generation sequencing (NGS) analysis of tumor DNA to determine new resistance markers. The aim of the study is to develop and validate bioinformatic algorithm for the search of tumor response predictors. The results of bioinformatics analysis are the genes, which may be determinants of resistance to anti - EGFR therapy.